Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD52 (CAMPATH1).
Hale G. Hale G. J Biol Regul Homeost Agents. 2001 Oct-Dec;15(4):386-91. J Biol Regul Homeost Agents. 2001. PMID: 11860230 Review. No abstract available.
Male-specific modification of human CD52.
Schröter S, Derr P, Conradt HS, Nimtz M, Hale G, Kirchhoff C. Schröter S, et al. Among authors: hale g. J Biol Chem. 1999 Oct 15;274(42):29862-73. doi: 10.1074/jbc.274.42.29862. J Biol Chem. 1999. PMID: 10514467 Free article.
Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, Ortin M, Freires M, Hale G, Waldmann H, Gordon-Smith EC, Marsh JC. Gupta V, et al. Among authors: hale g. Biol Blood Marrow Transplant. 2004 Dec;10(12):867-76. doi: 10.1016/j.bbmt.2004.09.001. Biol Blood Marrow Transplant. 2004. PMID: 15570255 Free article.
CAMPATH: from concept to clinic.
Waldmann H, Hale G. Waldmann H, et al. Among authors: hale g. Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-11. doi: 10.1098/rstb.2005.1702. Philos Trans R Soc Lond B Biol Sci. 2005. PMID: 16147535 Free PMC article. Review.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Lundin J, et al. Among authors: hale g. Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159. Blood. 2002. PMID: 12130484 Free article. Clinical Trial.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P. Hale G, et al. Blood. 2004 Aug 15;104(4):948-55. doi: 10.1182/blood-2004-02-0593. Epub 2004 Apr 15. Blood. 2004. PMID: 15090452 Free article. Clinical Trial.
755 results